Corneal transplantation

The Lancet

Volumn 379, Issue 9827, 2012, Pages 1749-1761

  Tan, Donald T H ^a,b,c   Dart, John K G ^d   Holland, Edward J ^e,f   Kinoshita, Shigeru ^g  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c National University Health System   (Singapore)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e CINCINNATI EYE INSTITUTE   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CYCLOSPORIN; EYE DROPS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SMALL INTERFERING RNA; STEROID; TACROLIMUS;

ARTICLE; BIOENGINEERING; BLINDNESS; CATARACT; CORNEA ENDOTHELIUM; CORNEA TRANSPLANTATION; CORNEAL ENDOTHELIAL CELL LOSS; ENDOTHELIAL KERATOPLASTY; FEMTOSECOND LASER; GLAUCOMA; GRAFT REJECTION; HUMAN; KERATOPLASTY; KERATOPROSTHESIS; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84860524818     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60437-1     Document Type: Review

References (98)

1. -2010 Eye Banking Statistical Report Eye Bank Association of America 2011. http://www.restoresight.org (accessed Nov. 28, 2011).
2. -2009 OPTN/SRTR Annual Report: Transplant Data 1999-2008: US Department of Health and Human Services. http://optn. transplant.hrsa.gov/ar2009/ (accessed Nov. 28, 2011).
3. Transplant Activity in the UK: National Health Service Blood and Transplant (NHSBT) Registry. http://www.uktransplant.org.uk/ukt/statistics/ transplant-activity-report/transplant-activity-report.jsp (accessed Nov. 28, 2011).
4. Luengo-Gimeno F, Tan DT, Mehta JS. Evolution of deep anterior lamellar keratoplasty (DALK). Ocul Surf 2011;9:98-110.
5. Keenan TD, Carley F, Yeates D, Jones MN, Rushton S, Goldacre MJ. Trends in corneal graft surgery in the UK. Br J Ophthalmol 2011;95:468-72.
6. Lee WB, Jacobs DS, Musch DC, Kaufman SC, Reinhart WJ, Shtein RM. Descemet's stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. Ophthalmology 2009;116:1818-30.
7. Reinhart WJ, Musch DC, Jacobs DS, Lee WB, Kaufman SC, Shtein RM. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty: a report by the American Academy of Ophthalmology. Ophthalmology 2011;118:209-18.
8. Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 2008;86:1720-24.
9. Ti SE, Scott JA, Janardhanan P, Tan D T. Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol 2007;143:755-62.
10. Anshu A, Parthasarathy A, Mehta JS, Htoon HM, Tan DT. Outcomes of therapeutic deep lamellar keratoplasty and penetrating keratoplasty for advanced infectious keratitis: a comparative study. Ophthalmology 2009;116:615-23.
11. Stewart RM, Jones MN, Batterbury M, Tole D, Larkin DF, Kaye SB. Effect of glaucoma on corneal graft survival according to indication for penetrating keratoplasty. Am J Ophthalmol 2011;151:257-62 e251.
12. Claesson M, Armitage WJ. Ten-year follow-up of graft survival and visual outcome after penetrating keratoplasty in Sweden. Cornea 2009;28:1124-29.
13. Anshu A, Lim LS, Htoon HM, Tan DT. Postoperative risk factors influencing corneal graft survival in the Singapore Corneal Transplant Study. Am J Ophthalmol 2011;151:442-48 e441.
14. Wagoner MD, Ba-Abbad R, Al-Mohaimeed M, Al-Swailem S, Zimmerman MB. Postoperative complications after primary adult optical penetrating keratoplasty: prevalence and impact on graft survival. Cornea 2009;28:385-94.
15. Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci 2003;44:3326-31.
16. Patel SV, Hodge DO, Bourne WM. Corneal endothelium and postoperative outcomes 15 years after penetrating keratoplasty. Am J Ophthalmol 2005;139:311-19.
17. Kelly TL, Williams KA, Coster DJ. Corneal transplantation for keratoconus: a registry study. Arch Ophthalmol 2011;129:691-97.
18. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology 2006;113:1633-38.
19. Anwar M, Teichmann KD. Deep lamellar keratoplasty: surgical techniques for anterior lamellar keratoplasty with and without baring of Descemet's membrane. Cornea 2002;21:374-83.
20. Price FW Jr, Price MO. Descemet's stripping with endothelial keratoplasty in 50 eyes: a refractive neutral corneal transplant. J Refract Surg 2005;21:339-45.
21. Melles GR, Ong TS, Ververs B, van der Wees J. Descemet membrane endothelial keratoplasty (DMEK). Cornea 2006;25:987-90.
22. McCauley MB, Price FW Jr, Price MO. Descemet membrane automated endothelial keratoplasty: hybrid technique combining DSAEK stability with DMEK visual results. J Cataract Refract Surg 2009;35:1659-64.
23. Price MO, Gorovoy M, Benetz BA, et al. Descemet's stripping automated endothelial keratoplasty outcomes compared with penetrating keratoplasty from the Cornea Donor Study. Ophthalmology 2010;117:438-44.
24. Terry MA. Endothelial keratoplasty: history, current state, and future directions. Cornea 2006;25:873-78.
25. Beauchemin C, Brunette I, Boisjoly H, Freeman EE, Popescu M, Lachaine J. Economic impact of the advent of posterior lamellar keratoplasty in Montreal, Quebec. Can J Ophthalmol 2010;45:243-51.
26. Espana EM, Huang B. Confocal microscopy study of donor-recipient interface after Descemet's stripping with endothelial keratoplasty. Br J Ophthalmol 2010;94:903-08.
27. Scorcia V, Matteoni S, Scorcia GB, Scorcia G, Busin M. Pentacam assessment of posterior lamellar grafts to explain hyperopization after Descemet's stripping automated endothelial keratoplasty. Ophthalmology 2009;116:1651-55.
28. McCauley MB, Price MO, Fairchild KM, Price DA, Price FW Jr. Prospective study of visual outcomes and endothelial survival with Descemet membrane automated endothelial keratoplasty. Cornea 2011;30:315-19.
29. Neff KD, Biber JM, Holland EJ. Comparison of central corneal graft thickness to visual acuity outcomes in endothelial keratoplasty. Cornea 2011;30:388-91.
30. Price MO, Fairchild KM, Price DA, Price FW Jr. Descemet's stripping endothelial keratoplasty five-year graft survival and endothelial cell loss. Ophthalmology 2011;118:725-29.
31. Khor WB, Mehta JS, Tan DT. Descemet stripping automated endothelial keratoplasty with a graft insertion device: surgical technique and early clinical results. Am J Ophthalmol 2011;151:223-32 e222.
32. Tseng SC. Concept and application of limbal stem cells. Eye (Lond) 1989;3:141-57.
33. Kinoshita S, Adachi W, Sotozono C, et al. Characteristics of the human ocular surface epithelium. Prog Retin Eye Res 2001;20:639-73.
34. Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Limbal epithelium in ocular surface wound healing. Invest Ophthalmol Vis Sci 1982;23:73-80.
35. Cotsarelis G, Cheng SZ, Dong G, Sun TT, Lavker RM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells. Cell 1989;57:201-09.
36. Dua HS, Shanmuganathan VA, Powell-Richards AO, Tighe PJ, Joseph A. Limbal epithelial crypts: a novel anatomical structure and a putative limbal stem cell niche. Br J Ophthalmol 2005;89:529-32.
37. Majo F, Rochat A, Nicolas M, Jaoude GA, Barrandon Y. Oligopotent stem cells are distributed throughout the mammalian ocular surface. Nature 2008;456:250-54.
38. Thoft RA. Keratoepithelioplasty. Am J Ophthalmol 1984;97:1-6.
39. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989;96:709-22.
40. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. N Engl J Med 1999;340:1697-703.
41. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet 1997;349:990-93.
42. Nakamura T, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. Br J Ophthalmol 2004;88:1280-84.
43. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010;363:147-55.
44. Sangwan VS, Basu S, Vemuganti GK, et al. Clinical outcomes of xeno-free autologous cultivated limbal epithelial transplantation: a 10-year study. Br J Ophthalmol 2011;95:1525-29.
45. Koizumi N, Inatomi T, Suzuki T, Sotozono C, Kinoshita S. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. Ophthalmology 2001;108:1569-74.
46. Nishida K, Yamato M, Hayashida Y, et al. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med 2004;351:1187-96.
47. Daya SM, Chan CC, Holland EJ. Cornea Society nomenclature for ocular surface rehabilitative procedures. Cornea 2011;30:1115-19.
48. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea 1995;14:473-84.
49. Tseng SC, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. Arch Ophthalmol 1998;116:431-41.
50. Holland EJ, Mogilishetty G, Skeens HM, et al. Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience. Cornea 2012; published online Feb. 13. doi:10.1097/ICO.0b013e31823f8b0c.
51. Cauchi PA, Ang GS, Azuara-Blanco A, Burr JM. A systematic literature review of surgical interventions for limbal stem cell deficiency in humans. Am J Ophthalmol 2008;146:251-59.
52. Daya SM, Watson A, Sharpe JR, et al. Outcomes and DNA analysis of ex vivo expanded stem cell allograft for ocular surface reconstruction. Ophthalmology 2005;112:470-77.
53. Inatomi T, Nakamura T, Koizumi N, Sotozono C, Yokoi N, Kinoshita S. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. Am J Ophthalmol 2006;141:267-75.
54. Klebe S, Coster DJ, Williams KA. Rejection and acceptance of corneal allografts. Curr Opin Organ Transplant 2009;14:4-9.
55. Claerhout I, Beele H, Kestelyn P. Graft failure: I. Endothelial cell loss. Int Ophthalmol 2008;28:165-73.
56. Kelly TL, Coster DJ, Williams KA. Repeat penetrating corneal transplantation in patients with keratoconus. Ophthalmology 2011;118:1538-42.
57. Panda A, Vanathi M, Kumar A, Dash Y, Priya S. Corneal graft rejection. Surv Ophthalmol 2007;52:375-96.
58. Nguyen NX, Seitz B, Martus P, Langenbucher A, Cursiefen C. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol 2007;144:318-19.
59. Ross AH, Jones MN, Nguyen DQ, et al. Long-term topical steroid treatment after penetrating keratoplasty in patients with pseudophakic bullous keratopathy. Ophthalmology 2009;116:2369-72.
60. Poon A, Constantinou M, Lamoureux E, Taylor HR. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol 2008;36:415-21.
61. Sinha R, Jhanji V, Verma K, Sharma N, Biswas NR, Vajpayee RB. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1167-72.
62. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 2011;152:33-39 e31.
63. Joseph A, Raj D, Shanmuganathan V, Powell RJ, Dua HS. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol 2007;91:51-55.
64. Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol 2010;150:179-84.
65. Birnbaum F, Mayweg S, Reis A, et al. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond) 2009;23:2063-70.
66. Falcinelli G, Falsini B, Taloni M, Colliardo P. Modified osteo-odonto-keratoprosthesis for treatment of corneal blindness: long-term anatomical and functional outcomes in 181 cases. Arch Ophthalmol 2005;123:1319-29.
67. Liu C, Okera S, Tandon R, Herold J, Hull C, Thorp S. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. Br J Ophthalmol 2008;92:1211-17.
68. Hicks CR, Crawford GJ, Dart JK, et al. AlphaCor: clinical outcomes. Cornea 2006;25:1034-42.
69. Zerbe BL, Belin M W, Ciolino JB. Results from the multicenter Boston Type 1 Keratoprosthesis Study. Ophthalmology 2006;113:1779 e1771-77.
70. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 2009;116:640-51.
71. Chew HF, Ayres BD, Hammersmith KM, et al. Boston keratoprosthesis outcomes and complications. Cornea 2009;28:989-96.
72. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 2011;118:1543-50.
73. Dohlman C, Harrisi-Dagher M. The Boston Keratoprosthesis: a new threadless design. Digital J Ophthalmol 2007;13.
74. Ament JD, Stryjewski TP, Pujari S, et al. Cost effectiveness of the type II Boston keratoprosthesis. Eye (Lond) 2011;25:342-49.
75. Chan CC, Holland EJ, Sawyer WI, Neff KD, Petersen MR, Riemann CD. Boston type 1 keratoprosthesis combined with silicone oil for treatment of hypotony in prephthisical eyes. Cornea 2011;30:1105-09.
76. Colby KA, Koo EB. Expanding indications for the Boston keratoprosthesis. Curr Opin Ophthalmol 2011;22:267-73.
77. Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MG, Dohlman CH. Keratoprosthesis: preoperative prognostic categories. Cornea 2001;20:19-23.
78. Ciralsky J, Papaliodis GN, Foster CS, Dohlman CH, Chodosh J. Keratoprosthesis in autoimmune disease. Ocul Immunol Inflamm 2010;18:275-80.
79. Durand ML, Dohlman CH. Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea 2009;28:896-901.
80. Chan CC, Holland EJ. Infectious endophthalmitis after Boston type 1 keratoprosthesis implantation. Cornea 2012;31:346-49.
81. Steinert RF, Ignacio TS, Sarayba MA. "Top hat"-shaped penetrating keratoplasty using the femtosecond laser. Am J Ophthalmol 2007;143:689-91.
82. Mehta JS, Parthasarthy A, Por YM, Cajucom-Uy H, Beuerman RW, Tan D. Femtosecond laser-assisted endothelial keratoplasty: a laboratory model. Cornea 2008;27:706-12.
83. Farid M, Steinert RF, Gaster RN, Chamberlain W, Lin A. Comparison of penetrating keratoplasty performed with a femtosecond laser zig-zag incision versus conventional blade trephination. Ophthalmology 2009;116:1638-43.
84. Shousha MA, Yoo SH, Kymionis GD, et al. Long-term results of femtosecond laser-assisted sutureless anterior lamellar keratoplasty. Ophthalmology 2011;118:315-23.
85. Griffith M, Osborne R, Munger R, et al. Functional human corneal equivalents constructed from cell lines. Science 1999;286:2169-72.
86. Ruberti JW, Zieske JD. Prelude to corneal tissue engineering - gaining control of collagen organization. Prog Retin Eye Res 2008;27:549-77.
87. Fagerholm P, Lagali NS, Merrett K, et al. A biosynthetic alternative to human donor tissue for inducing corneal regeneration: 24-month follow-up of a phase 1 clinical study. Sci Transl Med 2010;2:46ra61.
88. Lee JG, Ko MK, Kay EP. Endothelial mesenchymal transformation mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res 2012;95:35-39.
89. Senoo T, Obara Y, Joyce NC. EDTA: a promoter of proliferation in human corneal endothelium. Invest Ophthalmol Vis Sci 2000;41:2930-35.
90. Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res 2003;22:359-89.
91. Mimura T, Yamagami S, Usui T, et al. Long-term outcome of iron-endocytosing cultured corneal endothelial cell transplantation with magnetic attraction. Exp Eye Res 2005;80:149-57.
92. Sumide T, Nishida K, Yamato M, et al. Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. FASEB J 2006;20:392-94.
93. Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci 2009;50:3680-87.
94. Peh GS, Beuerman RW, Colman A, Tan DT, Mehta JS. Human corneal endothelial cell expansion for corneal endothelium transplantation: an overview. Transplantation 2011;91:811-19.
95. Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial cell sheet transplantation in a primate model. Invest Ophthalmol Vis Sci 2007;48:4519-26.
96. Kampik D, Ali RR, Larkin DF. Experimental gene transfer to the corneal endothelium. Exp Eye Res 2012;95:54-59.
97. Fuchsluger TA, Jurkunas U, Kazlauskas A, Dana R. Anti-apoptotic gene therapy prolongs survival of corneal endothelial cells during storage. Gene Ther 2011;18:778-87.
98. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol 2011;95:1006-09.